IL0011326795 - Common Stock
POLYPID LTD
NASDAQ:PYPD (4/24/2024, 3:30:00 PM)
4.5571
+0.07 (+1.62%)
PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
POLYPID LTD
18 Hasivim Street, P.O Box 7126
Petah Tikva 49537
P: 972747195700
CEO: Amir Weisberg
Employees: 65
Website: https://www.polypid.com
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company...
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections ...
Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up;...
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PolyPid announces $16.2M private placement financing with investors purchasing 3.4M shares at $4.81/share and receiving warrants to buy additional shares.
Here you can normally see the latest stock twits on PYPD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: